The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc’s GILD.O drug remdesivir.
The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.
The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.
- Nova Scotia aims to reduce mammogram wait times, enhance women’s health care
- Anthrax outbreak kills more than 50 animals, infects 12 people in Zambia
- Childhood Cancer Canada calls for $15M from feds as demand rises
- ‘E-dirt bikes are not toys’: E.R. doc fears more injuries after 2 kids hit in Edmonton
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.
The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.
(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)
Comments
Want to discuss? Please read our Commenting Policy first.